# Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy

> **NCT02349958** · PHASE2 · UNKNOWN · sponsor: **Bay Area Gynecology Oncology** · enrollment: 200 (estimated)

## Conditions studied

- Ovarian Cancer
- Peritoneal Cancer
- Fallopian Tube Cancer
- Uterine Cancer
- Mesotheliomas
- Gastrointestinal Cancers
- Cervical Cancer

## Interventions

- **DEVICE:** HIPEC: MMC 30mg @ T0, 10mg @ T45min
- **DEVICE:** HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0
- **DEVICE:** HIPEC: CDDP 75 mg/m2 @T0
- **DEVICE:** HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0

## Key facts

- **NCT ID:** NCT02349958
- **Lead sponsor:** Bay Area Gynecology Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-09
- **Primary completion:** 2022-01
- **Final completion:** 2022-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2019-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02349958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02349958, "Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02349958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*